A draft appraisal document issued this month recommends second-line use of risedronate and etidronite in primary and secondary prevention of fractures in women who cannot tolerate alendronate, subject to T-scores.
Professor David Reid, chair of the National Osteoporosis Society medical board, said: 'It is good news that NICE recognises there is more than one drug out there, but using T-scores to decide which treatment a patient should be given is unworkable.'
Strontium ranelate is recommended as an alternative for women who cannot tolerate alendronate and risedronate.
Comment below and tell us what you think
Quick search - use * for an abbreviated search, eg nico*
With spiralling energy costs, it is important to adopt policies that can save money as well as the e... Read More
A radical programme promises to transform care for people with diabetes, writes Fiona Barr. Read More
Health and education are working together to improve young people's health and wellbeing, writes Sar... Read More
Contributed by Mr Ranan DasGupta, specialist registrar and Mr Jonathon Olsburgh, consultant urologic... Read more
By Dr Helen Hosker, GP and clinical commissioning lead for stroke, NHS Manchester, and Dr Pippa Tyrr... Read more
Although it is one of the most common autoimmune diseases, Sjogren's syndrome remains underdiagnosed... Read more
Janssen-Cilag has launched Intelence (etravirine) for the treatment of HIV infection in antiretrovir... Read more
Janssen-Cilag has launched Doribax (doripenem) for the treatment of nosocomial pneumonia (including ... Read more
Ebixa (memantine) is now licensed for once-daily administration in the treatment of patients with mo... Read more
This site is intended for healthcare professionals only
Comments
Only registered users may comment. Log in now or register for a free account.